After completing a course of treatment, there are few words that sound better to a patient than “complete remission.” It’s an indication that the treatment has worked, and there is no evidence of cancer based on scans or lab tests.
However, there is a different phrase that can be somewhat confusing to patients – minimal residual disease (MRD). This term is used often by physicians when treating patients with blood cancers, such...
Natural killer cells – or NK cells – are part of our immune system. They patrol our bodies for abnormal cells like cancer and destroy them...
Lori Shults didn’t know much about clinical trials when she first came to MD Anderson in May 2017. “I thought they involved some people getting...
MD Anderson’s Moon Shots Program™ increases the speed at which our experts turn their research into new cancer treatment options for patients. At the core of this ambitious initiative are 10 research platforms, which provide the 13 disease-specific Moon Shots with specialized equipment, knowledge and data analysis tools.
To learn how the platform impacts our immunotherapy research and cancer treatment, we spoke with the Immunotherapy...
Courage. Hope. Love. Faith. Strength. Wisdom. These are a few of the gifts that our cancer survivors shared with us on Cancerwise this past...
A cancer diagnosis can provoke a range of emotions and prompt endless questions. So throughout the year, we shared dozens of insights from...
Some people think you can only get breast cancer from your mother’s side of the family. But that’s a myth. Breast cancer can come just as...
Until I was diagnosed with stage I triple-negative breast cancer in December 2016, I didn’t know much about immunotherapy. But as an executive...
MD Anderson’s Moon Shots Program™ is designed to reduce the time it takes to move promising cancer discoveries into the clinic, where they...
Giulio Draetta, M.D., Ph.D., is a true global citizen whose passion for discovery put his career on a winding path with universities and pharmaceutical...